| A410 |
Finotonlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research. |
|
| A411 |
Geptanolimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer. |
|
| A412 |
Iparomlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research. |
|
| A413 |
Pidilizumab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research. |
|
| A414 |
Sasanlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells. |
|
| DC67045 |
Solriamfetol
Featured
|
Solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects. Solriamfetol binds to dopamine and norepinephrine transporters, so it can inhibit reuptake of dopamine and norepinephrine. Solriamfetol treatment significantly improves the ability to stay awake and subjective symptoms of excessive sleepiness in adults with narcolepsy. |
|
| A415 |
Spartalizumab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC). |
|
| A416 |
Pimivalimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor. |
|
| A417 |
Toripalimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma. |
|
| A418 |
Zimberelimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma. |
|
| A419 |
Prolgolimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma. |
|
| A420 |
Nofazinlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research. |
|
| A421 |
Cetrelimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo. |
|
| A422 |
Budigalimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function. |
|
| A423 |
Ezabenlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo. |
|
| A424 |
Serplulimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer. |
|
| A425 |
Penpulimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities. |
|
| A426 |
Balstilimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibod)
Featured
|
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1. |
|
| A427 |
UCB patent anti-PD-1 Biosimilar（Anti-PDCD1 / PD-1 / CD279 Reference Antibody）
Featured
|
|
|
| A428 |
MOR-8457 Biosimilar（Anti-PDGFB Reference Antibody）
Featured
|
|
|
| A429 |
Thrombogenics patent anti-PDGF-C Biosimilar（Anti-PDGFC / VEGFE Reference Antibody）
Featured
|
|
|
| A430 |
Olaratumab Biosimilar（Anti-PDGFRA / CD140a Reference Antibody）
Featured
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity. |
|
| A431 |
Tovetumab Biosimilar（Anti-PDGFRA / CD140a Reference Antibody）
Featured
|
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC). |
|
| A432 |
IMC-2C5 Biosimilar（Anti-PDGFRB / CD140b Reference Antibody）
Featured
|
|
|
| A433 |
Novo Nordisk patent anti-PGLYRP1 Biosimilar（Anti-PGLYRP1 / PGRP-S Reference Antibody）
Featured
|
|
|
| A434 |
Bavituximab Biosimilar（Anti-Phosphatidylserine Reference Antibody）
Featured
|
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer. |
|
| A435 |
ATH3G10 Biosimilar（Anti-Phosphorylcholine Reference Antibody）
Featured
|
|
|
| A436 |
Diaccurate patent anti-sPLA2-GIB Biosimilar(Anti-PLA2G1B Reference Antibody)
Featured
|
|
|
| A437 |
ATN-658 Biosimilar（Anti-PLAUR / uPAR / CD87 Reference Antibody）
Featured
|
|
|
| A438 |
Genentech anti-PMEL17 Biosimilar（Anti-PMEL Reference Antibody）
Featured
|
|
|
